INMED PHARMACEUTICALS INC. Increase Decrease In Operating Lease Liability
INMED PHARMACEUTICALS INC. (INM) reported Increase Decrease In Operating Lease Liability of -$745.53 thousand for the 12-month period ending 2026-06-30, per its S-4/A filed 2026-09-09.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-09-09
- INMED PHARMACEUTICALS INC. increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$418.13K.
- INMED PHARMACEUTICALS INC. increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$110.07K.
- INMED PHARMACEUTICALS INC. increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$109.92K.
- INMED PHARMACEUTICALS INC. increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$107.41K.
- INMED PHARMACEUTICALS INC. increase decrease in operating lease liability for fiscal 2023 was -$426.57K.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$418.13K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$528.20K derived: sum of 2 quarters · filed 2026-09-09 | -$638.12K derived: sum of 3 quarters · filed 2026-09-09 | -$745.53K S-4/A · filed 2026-09-09 |
| 2026-03-31 | -$110.07K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | -$219.98K derived: sum of 2 quarters · filed 2026-07-02 | -$327.39K S-4 · filed 2026-07-02 | -$442.05K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-12-31 | -$109.92K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$217.33K 10-Q · filed 2026-02-11 | -$331.99K derived: sum of 3 quarters · filed 2026-09-09 | -$443.29K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-09-30 | -$107.41K 10-Q · filed 2025-11-06 | -$222.07K derived: sum of 2 quarters · filed 2026-09-09 | -$333.37K derived: sum of 3 quarters · filed 2026-09-09 | -$430.79K derived: sum of 4 quarters · filed 2026-09-09 |
| 2025-06-30 | -$114.66K derived: S-4/A 12 month − S-4 9 month · filed 2026-09-09 | -$225.96K derived: sum of 2 quarters · filed 2026-09-09 | -$323.37K derived: sum of 3 quarters · filed 2026-09-09 | -$429.88K S-4/A · filed 2026-09-09 |
| 2025-03-31 | -$111.30K derived: S-4 9 month − 10-Q 6 month · filed 2026-07-02 | -$208.72K derived: sum of 2 quarters · filed 2026-07-02 | -$315.22K S-4 · filed 2026-07-02 | -$423.34K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-12-31 | -$97.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-11 | -$203.92K 10-Q · filed 2026-02-11 | -$312.04K derived: sum of 3 quarters · filed 2026-07-02 | -$408.24K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-09-30 | -$106.51K 10-Q · filed 2025-11-06 | -$214.63K derived: sum of 2 quarters · filed 2026-07-02 | -$310.82K derived: sum of 3 quarters · filed 2026-07-02 | -$405.22K derived: sum of 4 quarters · filed 2026-07-02 |
| 2024-06-30 | -$108.12K derived: S-4 12 month − 10-Q 9 month · filed 2026-07-02 | -$204.31K derived: sum of 2 quarters · filed 2026-07-02 | -$298.71K derived: sum of 3 quarters · filed 2026-07-02 | -$397.42K S-4 · filed 2026-07-02 |
| 2024-03-31 | -$96.19K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | -$190.59K derived: sum of 2 quarters · filed 2025-05-12 | -$289.30K 10-Q · filed 2025-05-12 | |
| 2023-12-31 | -$94.40K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-12 | -$193.11K 10-Q · filed 2025-02-12 | ||
| 2023-09-30 | -$98.71K 10-Q · filed 2024-11-14 | |||
| 2023-06-30 | -$426.57K 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |